<DOC>
	<DOC>NCT00045786</DOC>
	<brief_summary>The primary objective of the study is to assess the safety of CC-1088 to patients with myelodysplastic syndromes (MDS).</brief_summary>
	<brief_title>Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Eligible patients must have a diagnosis of MDS of at least 12 weeks that is not therapy related. Patient must be able to adhere to the study visit schedule and other protocol requirements. Patient must understand and voluntarily sign an informed consent document. Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy test. Women must not be pregnant or lactating.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2004</verification_date>
	<keyword>myelodysplastic syndrome</keyword>
</DOC>